Review
Gastroenterology & Hepatology
Casper Steenholdt, Pernille Dige Ovesen, Jorn Brynskov, Jakob Benedict Seidelin
Summary: This systematic review analyzed the efficacy, safety, and integration of Tofacitinib in the treatment of acute severe ulcerative colitis (ASUC). The results showed that Tofacitinib has promising results in ASUC with high short-term colectomy-free survival. However, larger and high-quality studies are still needed to further evaluate its effectiveness.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Edward V. Loftus, Daniel C. Baumgart, Krisztina Gecse, Jami A. Kinnucan, Susan B. Connelly, Leonardo Salese, Chinyu Su, Kenneth K. Kwok, John C. Woolcott, Alessandro Armuzzi
Summary: CDIs in patients with UC receiving tofacitinib were infrequent, with mild-moderate severity, and most cases resolved with treatment.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Biochemistry & Molecular Biology
Michelle Temby, Theresa L. Boye, Jacqueline Hoang, Ole H. Nielsen, John Gubatan
Summary: This article reviews the role of kinase signaling pathways in colitis-associated colon cancer, including MAPK, CDK, autophagy-activated kinases, JAK-STAT, and other kinases. It also discusses the involvement of JAK-STAT signaling in the pathogenesis of inflammatory bowel disease (IBD) and the potential use of JAK inhibitors for treating IBD.
Review
Gastroenterology & Hepatology
Peter M. Irving, Yvette Leung, Marla C. Dubinsky
Summary: This study reviews published evidence on the use of two different dosing strategies of tofacitinib in ulcerative colitis treatment and provides expert interpretation of the clinical implications of dose adjustment based on real-world data and clinical scenarios.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Medicine, General & Internal
Viktor Domislovic, Joachim Hog Mortensen, Majken Lindholm, Morten Asser Kaarsdal, Marko Brinar, Ana Barisic, Tina Manon-Jensen, Zeljko Krznaric
Summary: This study investigated serum biomarkers of ECM remodeling in patients with inflammatory bowel disease (IBD), and found that a combination of C4M, C3M, and PRO-C3 biomarkers may potentially serve as a biomarker to differentiate moderate to severe endoscopic disease.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Engineering, Biomedical
Niranjan G. Kotla, Rajbir Singh, Becca Baby, Swetha Rasala, Jawad Rasool, Sean O. Hynes, Darrell Martin, Laurence J. Egan, Praveen K. Vemula, Venkatakrishna R. Jala, Yury Rochev, Abhay Pandit
Summary: Delivering drugs directly to inflamed intestinal sites to treat inflammatory bowel disease (IBD) is a challenge, but the development of targeted carrier systems such as IT-NCs shows promising therapeutic potential in improving treatment efficacy.
Article
Gastroenterology & Hepatology
Julien Kirchgesner, Rishi J. Desai, Maria C. Schneeweiss, Laurent Beaugerie, Sebastian Schneeweiss, Seoyoung C. Kim
Summary: Combination therapy with vedolizumab and thiopurines is associated with a lower risk of treatment failure compared to vedolizumab monotherapy in patients with CD, but the effect is less pronounced in UC.
Article
Pathology
F. Weber, K. Eger, C. March, R. S. Croner, F. Meyer
Summary: The researchers reported a rare complication in a patient with ulcerative colitis who developed acute appendicitis while undergoing immunosuppressive/anti-inflammatory treatment. They suggested that this could be a specific side effect of immunomodulation therapy or related to intestinal drainage defect.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Gastroenterology & Hepatology
Maria Chaparro, Ana Garre, Francisco Mesonero, Cristina Rodriguez, Manuel Barreiro-de Acosta, Jesus Martinez-Cadilla, Maria T. Arroyo, Noemi Mancenido, Monica Sierra-Ausin, Isabel Vera-Mendoza, Maria Jose Casanova, Pilar Nos, Carlos Gonzalez-Munoza, Teresa Martinez, Maia Bosca-Watts, Margalida Calafat, David Busquets, Eva Girona, Jordina Llao, Maria Dolores Martin-Arranz, Marta Piqueras, Laura Ramos, Gerard Suris, Fernando Bermejo, Ana Y. Carbajo, Diego Casas-Deza, Agnes Fernandez-Clotet, Maria J. Garcia, Daniel Ginard, Ana Gutierrez-Casbas, Luis Hernandez, Alfredo J. Lucendo, Lucia Marquez, Olga Merino-Ochoa, Francisco J. Rancel, Carlos Taxonera, Antonio Lopez Sanroman, Saioa Rubio, Eugeni Domenech, Javier P. Gisbert
Summary: The study findings indicate that tofacitinib is effective and safe in treating active ulcerative colitis. However, a significant proportion of patients discontinue the drug over time, mainly due to primary failure.
JOURNAL OF CROHNS & COLITIS
(2021)
Review
Immunology
Yuanzhuo Wang, Ziqi Wan, Rui Jin, Tianming Xu, Yan Ouyang, Baihui Wang, Gechong Ruan, Xiaoyin Bai
Summary: Extraintestinal manifestations (EIMs) are common in patients with inflammatory bowel disease (IBD) and managing these manifestations is difficult. Recent research has found that tofacitinib (TOF) may be a promising option for treating EIMs. TOF may benefit EIMs in ulcerative colitis, and higher doses and longer treatment times may increase its effectiveness. However, more specific research and large prospective studies are needed.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Review
Gastroenterology & Hepatology
Klaus R. Herrlinger, Eduard F. Stange
Summary: This review examines the current guidelines for the treatment of inflammatory bowel disease (IBD) and suggests personalized treatment options based on individual clinical cases. The analysis of relevant literature suggests that combined use of drugs such as infliximab and azathioprine can improve treatment outcomes for Crohn's disease and ulcerative colitis. In cases of steroid-refractory ulcerative colitis, the preference should be given to infliximab plus azathioprine or upadacitinib.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Jurij Hanzel, Peter Bossuyt, Valerie Pittet, Mark Samaan, Monika Tripathi, Wladyslawa Czuber-Dochan, Johan Burisch, Salvatore Leone, Roberto Saldana, Filip Baert, Uri Kopylov, Susanna Jaghult, Michel Adamina, Naila Arebi, Krisztina Gecse
Summary: This study aimed to develop a core outcome set for real-world studies in adult patients with inflammatory bowel disease (IBD). Candidate outcomes and outcome measures were identified through a systematic review and a modified Delphi consensus process. The international panel agreed on the final core outcome set, which will facilitate the synthesis and generation of real-world evidence.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Uma Mahadevan, Millie D. Long, Sunanda Kane, Abhik Roy, Marla C. Dubinsky, Bruce E. Sands, Russell D. Cohen, Christina D. Chambers, William J. Sandborn
Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.
Article
Gastroenterology & Hepatology
Bharati D. Kochar, David Cheng, Tianxi Cai, Ashwin N. Ananthakrishnan
Summary: This retrospective cohort study using a US claims database found that tofacitinib, used to treat IBD, did not increase the risk of adverse thrombotic events compared to anti-TNF therapy.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Review
Immunology
Reza Yarani, Ali Shojaeian, Oana Palasca, Nadezhda T. Doncheva, Lars Juhl Jensen, Jan Gorodkin, Flemming Pociot
Summary: This review discusses the differential regulation of miRNAs in inflammatory bowel disease (IBD) and their potential diagnostic and therapeutic applications. Through literature curation and computational analysis, a consensus set of differentially expressed miRNAs in mucosal tissues was obtained. The role of these miRNAs and their potential targets in IBD are highlighted.
FRONTIERS IN IMMUNOLOGY
(2022)